Showing 4631-4640 of 5623 results for "".
- I-MED Pharma Launches Tearcheck Dry Eye Analysis in Canadahttps://modernod.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/I-MED Pharma announced the Canadian launch of tearcheck, a diagnostic and analyzing tool that performs 9 exams in under 10 minutes. The tearcheck was designed and developed by the French manufacturer E-Swin and offers the newest technological advancements to simplify dry eye d
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p
- FDA Fast-Tracks Novavax COVID-19 Vaccine NVXCoV2373https://modernod.com/news/fda-fast-tracks-novavax-covid-19-vaccine-nvxcov2373/2478517/Novavax said Monday that its experimental COVID-19 vaccine NVX-CoV2373 has received fast-track designation from the FDA. The company also reiterated that it expects to begin a pivotal phase 3 trial of the candidate in the US and Mexico by the end of November, data from which could be used to supp
- AAO Data: Experimental RNA Based Drug Addresses the Underlying Cause of Rare Eye Diseasehttps://modernod.com/news/aao-data-experimental-rna-based-drug-addresses-the-underlying-cause-of-rare-eye-disease/2478509/At the virtual AAO 2020 meeting, ProQR Therapeutics will present two posters on its lead product candidate sepofarsen for the treatment of the root cause of Leber congenital amaurosis 10 (LCA10), a rare eye disease that damages the development of the retina and causes severe vision loss. P
- Oxurion NV Confirms New Patents for THR-687 Issued by European and US Patent Officeshttps://modernod.com/news/oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices/2478504/Oxurion NV announced a strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME. The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-o
- COVID-19 Vaccine Safety Efforts to Feature App Tracking of Vulnerable Groupshttps://modernod.com/news/covid-19-vaccine-safety-efforts-to-feature-app-tracking-of-vulnerable-groups/2478501/Government health officials and drugmakers plan to roll out extra tools to detect whether COVID-19 vaccines cause any serious side effects once the shots are cleared for widespread use, aiming to fill gaps in existing safeguards given the expected speed and scope of
- First COVID-19 Vaccine Doses To Go To Health Workers, Say CDC Advisershttps://modernod.com/news/first-covid-19-vaccine-doses-to-go-to-health-workers-say-cdc-advisers/2478502/Health care workers will almost certainly get the first doses of COVID-19 vaccine in the U.S. when one is approved, according to Dr. José Romero, head of the committee that develops evidence-based immunization guidelines for the Centers for Disease Control and Prevention, as
- How Best to Combat Post-Keratoplasty Infections Isn’t Always Clearhttps://modernod.com/news/how-best-to-combat-post-keratoplasty-infections-isnt-always-clear/2478503/Infection is one of the most dreaded complications after ocular surgery. Although it is considered rare, the rate of fungal infections after corneal transplantation is nonetheless increasing in the United States. As detailed in a recent r
- Pfizer Goes Solo on U.S. Shot Distribution, Opting Out of Government Channelshttps://modernod.com/news/pfizer-goes-solo-on-u-s-shot-distribution-opting-out-of-government-channels/2478499/Pfizer had already made it quite clear that it doesn’t need the U.S. government to help distribute its COVID-19 vaccine, should it be authorized by the FDA. Now it’s putting an exclamation point on that declaration, according to a FiercePharma
- Technique to Regenerate Optic Nerve Offers Hope for Future Glaucoma Treatmenthttps://modernod.com/news/technique-to-regenerate-optic-nerve-offers-hope-for-future-glaucoma-treatment/2478496/Scientists have used gene therapy to regenerate damaged nerve fibres in the eye, in a discovery that could aid the development of new treatments for glaucoma, according to a Medical Xpress report. </